Surgical complications in solitary pancreas and combined pancreas-kidney transplantations

Am J Surg. 1992 Nov;164(5):546-51. doi: 10.1016/s0002-9610(05)81198-5.

Abstract

The benefits of pancreas transplantation (PT) must be weighed against the morbidity associated with the operative procedure and long-term immunosuppression. Over a 32-month period, we performed 73 PTs including 61 combined pancreas-kidney transplants (PKT) and 12 solitary PTs. In the PKT group, 25 reoperations were performed in 18 patients (29.5%) at a mean of 39 +/- 12 days after transplant. In the solitary PT group, 16 reoperations were performed in 8 recipients (66.7%, p = 0.03) at a mean of 87 +/- 12 days after PT (p < 0.01). In the PKT group, pancreas allograft survival was 93.4%. Vascular thrombosis resulted in the loss of two pancreas allografts. In the solitary PT group, pancreas allograft survival was 50% (p < 0.001), with 6 transplant pancreatectomies performed for either infectious (5) or vascular (1) complications. Surgical complications after PT are common (35.6% in this series), occur earlier in patients who undergo PKT, and are more frequent and morbid in patients undergoing solitary PT, especially after a previous kidney transplant. An aggressive surgical approach can lead to a high rate of pancreas allograft salvage without jeopardizing either the patient or the renal allograft.

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 1 / surgery
  • Female
  • Follow-Up Studies
  • Graft Survival
  • HLA Antigens
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Intraoperative Complications
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / methods
  • Male
  • Middle Aged
  • Organ Preservation
  • Pancreas Transplantation / adverse effects*
  • Pancreas Transplantation / methods
  • Pancreatitis / etiology
  • Reoperation
  • Retrospective Studies
  • Risk Factors
  • Surgical Wound Infection / etiology
  • Survival Rate
  • Tissue and Organ Procurement
  • Treatment Outcome

Substances

  • HLA Antigens
  • Immunosuppressive Agents